Article
作者: Liu, Qianqian ; Tang, Lin ; Wu, Dan ; Liu, Xiaoqiang ; Yin, Zundong ; Xu, Wenbo ; Liu, Xiaoyu ; Zhang, Shaobai ; Tan, Wenjie ; Hu, Weijun ; Zhang, Xianfeng ; Huang, Baoying ; Zheng, Yan ; Wang, Lei ; Wang, Fuzhen ; Zhao, Li ; Rodewald, Lawrence E ; Zheng, Hui ; Wang, Ruize ; Wang, Siquan ; Gao, George F ; Guan, Xuhua ; Ye, Fei ; Wang, Wenling ; Wang, Xiaoqi ; Ren, Jiao ; Wang, Cangning ; Deng, Yao ; An, Zhijie ; Yang, Haitao
BACKGROUND:Several COVID-19 vaccines are in widespread use in China. Few data exist on comparative immunogenicity of different COVID-19 vaccines given as booster doses. We aimed to assess neutralizing antibody levels raised by injectable and inhaled aerosolized recombinant adenovirus type 5 (Ad5)-vectored COVID-19 vaccine as a heterologous booster after an inactivated COVID-19 vaccine two-dose primary series.
METHODS:Using an open-label prospective cohort design, we recruited 136 individuals who had received inactivated vaccine primary series followed by either injectable or inhaled Ad5-vectored vaccine and measured neutralizing antibody titers against ancestral SARS-CoV-2 virus and Omicron BA.1 and BA.5 variants. We also measured neutralizing antibody levels in convalescent sera from 39 patients who recovered from Omicron BA.2 infection.
RESULTS:Six months after primary series vaccination, neutralizing immunity against ancestral SARS-CoV-2 was low and neutralizing immunity against Omicron (B.1.1.529) was lower. Boosting with Ad5-vectored vaccines induced a high immune response against ancestral SARS-CoV-2. Neutralizing responses against Omicron BA.5 were ≥ 80% lower than against ancestral SARS-CoV-2 in sera from prime-boost subjects and in convalescent sera from survivors of Omicron BA.2 infection. Inhaled aerosolized Ad5-vectored vaccine was associated with greater neutralizing titers than injectable Ad5-vectored vaccine against ancestral and Omicron SARS-CoV-2 variants.
CONCLUSIONS:These findings support the current strategy of heterologous boosting with injectable or inhaled Ad5-vectored SARS-CoV-2 vaccination of individuals primed with inactivated COVID-19 vaccine.